

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BBI LIFE SCIENCES CORPORATION**

### **BBI生命科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1035)**

#### **POSITIVE PROFIT ALERT**

This announcement is made by BBI Life Sciences Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders of the Company and potential investors that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the Company’s management, it is expected that the Group will record an increase in net profit of more than 30% for the six months ended June 30, 2018 as compared to the six months ended June 30, 2017. The expected increase in net profit is primarily attributed to the sustained and rapid development of the Group’s main business and the significant narrowing of Bionics Co., Ltd. (“**Bionics**”), a subsidiary of the Group.

The information set out in this announcement is only based on a preliminary assessment by the management of the Company based on the unaudited consolidated management accounts of the Company for the six months ended June 30, 2018 and other information currently available to the Company, which has not been reviewed or audited by the Company’s auditors. Details on the financial information for the six months ended June 30, 2018 to be disclosed in the interim results announcement of the Company shall prevail.

**Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**BBI Life Sciences Corporation**  
**Wang Qisong**  
Chairman

Hong Kong, 14 August 2018

*As of the date of this announcement, the Company’s executive directors are Mr. Wang Qisong, Ms. Wang Luojia and Ms. Wang Jin; the non-executive director is Mr. Zhou Mi; and the independent non-executive directors are Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun.*